|
|
"We are committed to helping UC patients better manage their condition,” said Roger Adsett, senior vice president of the GI business unit at Shire. “Offering greater financial support to those who may be struggling due to the current economic climate through our expanded Shire CARES PAP is a natural extension of the Shire mission.” More than 100,000 people with UC have been treated with Lialda, and many have benefited from the Shire PAP. The new Shire CARES PAP includes job loss prescription coverage for 2009, and financial assistance at no cost and shared cost levels. Additionally, the Shire CARES PAP offers a discounted copay pharmacy card program (not valid in Mass.) and a 30-day free trial of Lialda when patients join the Lialda UC Support Program. The Lialda UC Support program offers patients the added benefit of hearing from professionals for medical insight and advice through an unbranded patient education Web site. “We are thrilled to launch this new, more robust program,” said Mike Cola, president of the Specialty Pharmaceuticals business at Shire. “The program is designed to help patients with ulcerative colitis who are taking Lialda or Pentasa and are experiencing a financial hardship gain access to these treatments. This enhanced PAP is the first of many steps Shire is taking to reinforce our commitment to the patient community, and we are pleased that Lialda and Pentasa are leading the way.” The Shire CARES PAP has a simple enrollment process and offers free delivery of medicines for enrolled patients to their home or doctor's office for up to one year. Patients may be re-enrolled if they continue to need assistance and qualify for the Shire CARES PAP. To learn more about the Shire CARES PAP for Lialda and Pentasa medications, please call 1-888-CARES-55 to speak with a live representative, or visit www.lialda.com. Subscribe to our FREE Ezine and be eligible for Health News, discounted products/services and coupons related to your Health. We publish 24/7. HealthNewsDigest.com Top of Page
|
Contact
Us | Job Listings
| Help | Site
Map | About Us
Advertising
Information | HND
Press Release | Submit
Information | Disclaimer